Table 5 Changes in the incremental cost-effectiveness ratio (ICER) with changes in the prevalence of pulmonary NTM infections
| Â | Smear negative all | Smear negative HIV+ | ||
|---|---|---|---|---|
Prevalence NTM | TB+ | ICER (US $) | TB+ | ICER (US $) |
35% | 99 | 19.45 | 36 | 12.7 |
30% | 93 | 20.70 | 34 | 13.5 |
25% | 88 | 21.90 | 31 | 14.8 |
20% | 82 | 23.50 | 29 | 15.8 |
15% | 76 | 25.36 | 27 | 17.0 |
10% | 70 | 27.54 | 25 | 18.3 |
5% | 64 | 30.12 | 22 | 20.8 |